Constitutive, Mosaic Expression of TIE2 p. L914F During Mouse Development Causes Venous Malformation

Read full text
Authors: Lindsay J. Bischoff, Chhiring Sherpa, Sandra Schrenk, Elisa Boscolo
Cited by: 1
References: 27

Abstract

ABSTRACT The hyperactivating p.L914F mutation in TIE2, a receptor tyrosine kinase essential for vascular development and function, drives sporadic venous malformation (VM). While germline or early developmental expression of this mutation is thought to be lethal, mosaic or somatic expression is expected to result in VM disease. However, this has never been shown experimentally. Therefore, we utilized a genetic murine model of TIE2 p.L914F to examine the effects of the mutation in the mosaic condition. Using an mTmG reporter mouse, we show that the CMV‐Cre mouse line drives mosaic Cre recombination during early embryonic development. We then crossed B6‐Tg(Rosa26‐TIE2 L914F ) EBos ( TIE2 L914F ) mice to CMV‐Cre mice to drive mosaic expression of TIE2 p.L914F during development. The offspring of these mice did not show the expected Mendelian ratio of mutant to control animals, indicating that mutant mice experienced partial lethality. Furthermore, surviving CMV‐Cre;TIE2 L914F mice developed massively enlarged venous/capillary vessels in various tissues, reminiscent of the VM phenotype. In this study, we show that mosaic embryonic expression of the VM‐causative mutation TIE2 p.L914F causes partial embryonic lethality and the formation of VM in surviving offspring. This is a novel in vivo model of mutant TIE2‐driven VM disease which illustrates that the extent of the mutational event during development will contribute to varying levels of severity in the VM phenotype.

Fields of Study & Subjects

Vascular Malformations and Hemangiomas Diagnosis and Treatment of Venous Diseases Vascular Malformations Diagnosis and Treatment

Publication details

Journal / source
The FASEB Journal
Publisher
Wiley
Volume
40
Issue
9
Pages
e71862–e71862
Publication date
30 April 2026
Language
EN